DOCK2 Knockout A2780 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal population of human A2780 ovarian carcinoma cells with targeted disruption of the DOCK2 gene. This heterogeneous knockout pool, produced without single-cell cloning, offers a versatile loss-of-function model while retaining natural genetic variability. Supplied as viable cells, it enables direct experimentation on DOCK2 deficiency within a high-grade serous ovarian carcinoma context.
The parental A2780 cell line, established from an untreated patient with ovarian endometrioid adenocarcinoma, serves as a well-characterized model for high-grade serous ovarian carcinoma (HGSOC). A2780 cells exhibit epithelial features and are extensively used to study tumor biology, drug responses, and metastatic mechanisms due to their reproducible growth and compatibility with genetic modification.
DOCK2 functions as a guanine nucleotide exchange factor (GEF) specifically for Rac1 and Rac2 GTPases. Upon chemokine receptor engagement (e.g., CXCR4, CCR7), PI3K-generated PIP3 and the adaptor ELMO1 recruit DOCK2 to the plasma membrane, where it activates Rac. This triggers a signaling cascade involving PAK kinases, the WAVE complex, and Arp2/3-mediated actin polymerization, culminating in lamellipodia formation and directed cell migration. Though primarily characterized in lymphocytes, DOCK2 expression in epithelial tumors suggests broader roles in cytoskeletal dynamics and cell motility.
In the A2780 ovarian carcinoma setting, DOCK2 knockout allows investigation of its potential contributions to cancer cell-autonomous behaviors such as migration and invasion. By ablating DOCK2, researchers can examine its impact on Rac-driven actin reorganization, chemokine responsiveness, and interactions with the tumor microenvironment. This model is particularly useful for exploring non-hematopoietic functions of DOCK2 and its possible involvement in tumor immune evasion mechanisms.
Key applications include transwell migration and wound healing assays to assess motility, immunofluorescence analysis of actin structures, and immunoblotting or RT-qPCR for target validation. Co-culture experiments with immune cells can probe tumor-immune crosstalk, while Rac1 activation assays and phospho-signaling profiling elucidate downstream pathways. Moreover, drug sensitivity screens may identify DOCK2-dependent vulnerabilities. These polyclonal knockout cells thus provide a robust tool for dissecting DOCK2-mediated processes in ovarian cancer biology and beyond. For further details or to request supporting data, please reach out to Ascent Research.
